Infection et TAVI |
| |
Affiliation: | 1. CAMC Health Education and Research Institute, Charleston, West Virginia;2. CAMC Vascular Center of Excellence, Charleston Area Medical Center, Charleston, West Virginia;3. Texas Tech University Health Sciences Center, El Paso, Texas;1. The Warren Alpert Medical School of Brown University and Lifespan Cardiovascular Institute, Providence, Rhode Island;2. University of Nebraska Medical Center, Omaha, Nebraska;3. Statistical Consultant, Lifespan Cardiovascular Institute, Providence, Rhode Island |
| |
Abstract: | Since trans-catheter valve implantation (TAVI) has emerged for severe symptomatic aortic stenosis treatment, infective endocarditis (IE) appears as a rare but severe complication. Like surgical aortic valve remplacement infective endocarditis (SAVR-IE), TAVI-IE has a noxious impact on morbidity and mortality. Compared to SAVR-IE, TAVI-IE present some similarities as well as differences. Most TAVI-IE occurred during the first year and enterococcus is the more common pathogen. A multimodality imaging approach including echocardiography, multislice computed tomography (CT) and positron emission tomography-CT with blood culture is necessary for the diagnosis. In this high-risk population, the vast majority of TAVI-IE patients are treated with antibiotic therapy alone. Consequently to the expanded indication, the increasing number of TAVI-IE will appear more frequently. If initially only few clinical cases of IE were reported, sparse observational multicenter registries have now been published. Relevant differences were noted on these registries, but some recent publications have provided new informations on IE. The present review reports incidence, symptoms, microbiological profil, risk factors and clinicals outcomes of TAVI-IE. Eventually, we describe the management and the treatment of IE in the context of TAVI. |
| |
Keywords: | Aortic stenosis Trans-catheter aortic valve implantation Infective endocarditis |
本文献已被 ScienceDirect 等数据库收录! |
|